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Summary Background. Patch tests help to confirm the aetiology of the cutaneous adverse drug
reactions involving delayed hypersensitivity mechanisms, but the results vary with the
pattern of skin reaction and the culprit drug.
Objectives. To analyse the results of patch tests in patients with cutaneous adverse
drug reactions imputable to clindamycin and assess their contribution to the diagnosis.
Patients andmethods. Between 2005 and 2009, we studied patients with delayed
cutaneous adverse drug reactions following administration of clindamycin, usually
associated with other drugs. After resolution of the cutaneous adverse drug reaction,
patch tests were performed with a series of antibiotics, including pure clindamycin 10%
in petrolatum.
Results. We studied 30 patients (23 females and 7 males) aged 33–86 years (mean
59.97 years)withgeneralizedmaculopapularexanthemawhereclindamycinwasamong
thehighly suspecteddrugs. Twopatients hadaprevious positive involuntary rechallenge.
Patch tests with clindamycin were positive in 9 of 30 patients (30%). More than 50
control patients patch tested with clindamycin were negative.
Discussion. We considered the positive patch tests results with clindamycin, in the
9 patients with maculopapular exantema, to be specific, versus the negative results
observed in the control group. Although the sensitivity is low (30%), they confirmed the
responsibility of this antibiotic in cutaneous adverse drug reactions in which, with only
chronological criteria, it was not possible to conclude on the culprit drug.
Key words: clindamycin; cutaneous adverse drug reaction; drug hypersensitivity;
maculopapular exanthema; patch tests.
Clindamycin, a synthetic antibiotic from the class of
lincomycins, is a bacteriostatic agent inhibiting bacterial
protein synthesis, and is used in the treatment of
infections caused by anaerobic and aerobic Gram-positive
bacteria, some protozoa (Toxoplasma gondii, Plasmodium
falciparum, Babesia spp.) and fungi (Pneumocystis jiroveci)
(1–3).
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Side effects include: diarrhoea, pseudomembranous
colitis, metallic taste, transitory increase in serum of
aminotransferases, granulocytopenia, thrombocytope-
nia, and rash (4). Cutaneous adverse drug reactions to
clindamycin are usually considered to be rare, but in pub-
lications they are reported to occur in <1% up to 10.5%
of treated patients (2). The majority of these reactions are
macular and maculopapular exanthema, although the
Stevens–Johnson syndrome and, more recently, several
cases of acute generalized exanthematous pustulosis have
been associated with clindamycin (4–9).
Skin tests, and particularly patch tests, have become
popular in the diagnosis of cutaneous adverse drug
reactions, allowing the identification or confirmation of
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the aetiological agent in some cases. Nevertheless, patch
test reactivity is highly variable, depending mainly on
the clinical characteristics of the cutaneous adverse drug
reaction and on the culprit drug (10).
In this study,we analysed patch tests results in patients





of the Coimbra University Hospital, we studied 30
patientswithdelayedcutaneous reactionsassociatedwith
clindamycin (Fig. 1).
The clinical characteristics of the drug eruption, the
time elapsed between drug introduction and initiation
of the rash, the infections that motivated treatment,
the concomitant drugs used and the treatment were
evaluated.
Patch testswere performed6–12 weeks after complete
resolution of the drug eruption. Tests were applied on
the upper back, in Finn Chambers® on Scanpor®, and
Fig. 1. Maculopapular exanthema induced by clindamycin.
the readings were performed on D2 and D3 or D4,
according to the guidelines of the International Contact
Dermatitis Research Group. Only + or stronger reactions
were considered.
All patients were tested with the European base-
line series of allergens, a series of systemic antibiotics
(Chemotechnique® Diagnostics, Vellinge, Sweden), and
pure clindamycin at 10% in petrolatum, as usually
recommended for performing patch testing with other
antibiotics (10). Clindamycinwas initially supplied by the
pharmaceutical industry and prepared at our laboratory
and,more recently,wasobtained fromChemotechnique®
Diagnostics. Additionally, the powder from capsules of
two commercial preparations of clindamycin (Dalacin C®
and Clindamycin Atral®) were diluted in pet. so that the
final concentration of clindamycin in the peparation was
10%. In individual cases, drugs administered concomi-
tantly with clindamycin that were not part of the drug
series from Chemotechnique® Diagnostics [e.g. other
antibiotics and non-steroidal anti-inflammatory drugs
(NSAIDs)]werealsopreparedat10%pet.,witheitherpure
products supplied by the pharmaceutical industry (cefa-
zolin and cefoxitin) or commercial preparations, namely
vancomycin (Vancomycin Labesfal®) and levofloxacin
(Tarivid®).
Pure clindamycin at 10% pet. and prepared from
commercial preparations was also tested in 42 controls
with cutaneous adverse drug reactions attributed to other
antibiotics and in nine patients exposed to clindamycin
without cutaneous adverse drug reactions.
Results
A total of 30 patients (23 females and 7 males) with ages
ranging from 33 to 86 years (59.97 ± 13.21 years) were
included in the study.
They had suffered from a variety of infections (27
with severe erysipelas, 1 with osteomyelitis, and 2 with
dental abscesses), andhad thereforebeen treatedwithoral
clindamycin (150–300mg every 6–8 h) and with other
antibiotics in29cases, namely cefazolin or cefoxitin in26,
clarithromycin in 1, levofloxacin in 1, and vancomycin
in 1; 2 had been treated with NSAIDs.
They all developed a generalized, pruriginous, mac-
ulopapular exanthema that began 2–12 days (mean
7.9 ± 2.2 days) after the introduction of clindamycin.
Two patients with recurring erysipelas developed a
similar maculopapular exanthema within 48 h of
the administration of clindamycin and a different
cephalosporin.
Patients were treated with topical steroids, oral
antihistamines and, in 15 patients, also oral corti-
costeroids. Clindamycin was stopped in all patients
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Table 1. Clinical data of patients subjected to patch testing





1 66/M Erysipelas Cly + Cefx 10 Yes
2 72/F Erysipelas Cly + Cefx 10 —
3 66/F Erysipelas Cly + Cefz 10 Yes
4 71/F Erysipelas Cly + Levo 9 —
5 76/F Erysipelas Cly + Cefa 9 Yes
6 43/F Erysipelas Cly + Cefx/Cefz 9 Yes
7 59/F Erysipelas Cly + Cefa/Ceftz 8 Yes
8 79/F Erysipelas Cly + Cefz 10 —
9 53/M Erysipelas Cly + Cefz 8 Yes
10 66/F Erysipelas Cly + Cefa 7 Yes
11 52/F Erysipelas Cly + Cefx/Cefa 9 Yes
12 52/F Erysipelas Cly + Cefx 7 Yes
13 67/F Erysipelas Cly + Cefx 8 Yes
14 61/F Erysipelas Cly + Cefa 9 —
15 75/M Erysipelas Cly + Cefx 8 —
16 55/F Erysipelas Cly + Cefx 3 Yes
17 70/F Erysipelas Cly + Cefz 7 —
18 40/M Erysipelas Cly + Cefz 5 —
19 59/F Erysipelas Cly + Cefz 8 —
20 86/F Erysipelas Cly + Cefx 8 Yes
21 69/F Osteomyelitis Cly + Vanc + Te 10 —
22 62/F Erysipelas Cly + Cefx 9 —
23 53/M Erysipelas Cly + Cefx 8 Yes
24 62/F Erysipelas Cly + Cefz 7 —
25 33/F Dental abscess Cly + Clar 2 —
26 45/F Dental abscess Cly + Nim 12 Yes
27 60/M Erysipelas Cly + Cefx 4 Yes
28 69/F Erysipelas Cly + Cefz 8 —
29 45/F Erysipelas Cly + Cefx 7 —







Mean = 7.9 ± 2.2 days Total = 15
Cefa, cefaclor; Cefx, cefoxitin; Cefz, cefazolin; Ceftz, ceftazidime; Clar, clarithromycin; Cly, clindamycin; Levo, levofloxacin; Nim, nimesulide;
Te, tenoxicam; Vanc, vancomycin; F, female; M, male.
and, eventually, so were other antibiotics with the
same degree of imputability. In patients observed
in more recent years, after the beginning of the
maculopapular exanthema, the cephalosporin intro-
duced concomitantly with clindamycin was contin-
ued, with no delay in the resolution of the rash.
When still needed, the antibiotics were replaced by
levofloxacin or clarithromycin. For patient details, see
Table 1.
In 9 of the 30 patients studied (30%), we observed
positive patch test reactions (+ or ++) to clindamycin,
with reactivities of similar intensity with either the pure
powder or the powder of the commercial capsules (Fig. 2).
One patient had a simultaneous positive reaction to
cefoxitin 10% pet. (Fig. 3). There were no reactions
to other antibiotics or drugs used concomitantly with
clindamycin, and none of the controls reacted to
clindamycin preparations.
In 10 patients (33.3%), there was reactivity to
allergens of the European baseline series, mainly to
nickel sulfate (4 patients, 13.3%) and the topical drug-
related allergens Myroxylon pereirae (4), fragrance mixes
I and II (3), lanolin (wool alcohols) (2), thimerosal (2),
and caine mix (2), reflecting the high number of
patients with leg ulcers or chronic venous insuffi-
ciency who developed erysipelas of the lower limbs
(Table 2).
Discussion
Patch testing can be a useful complementary diagnostic
method in the study of cutaneous adverse drug reactions,
particularly when there is suspicion of the involvement
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Fig. 2. Positive reactions to clindamycin, both pure powder and the
powder of the commercial capsules (Dalacin C® and Clindamycin
Atral®), prepared at 10% pet.
Fig. 3. Positive reaction to cefoxitin and clindamycin in patient 24.
of a delayed hypersensitivity reaction, namely in macu-
lopapular exanthema, drug rash with eosinophilia and
systemic symptoms (DRESS) (11), acute generalized
exanthematous pustulosis, fixed drug eruption and,
eventually, also in Stevens–Johnson syndrome/toxic
epidermal necrolysis (12). In these delayed cutaneous
adverse drug reactions, patch test reactivity varies
according to the tested drug and the clinical pattern
of the cutaneous adverse drug reaction, being higher in
cases of maculopapular exanthema andwith some drugs,
such as β-lactam antibiotics and carbamazepine (11,
13). However, patch test reactivity in these cutaneous
adverse drug reactions is significantly inferior to that in
allergic contact dermatitis, the paradigm of a delayed
hypersensitivity skin immune reaction. There are several
possible reasons for false-negative reactions: the allergen
might be a metabolite of the drug that is not produced
from skin application, the concentration or the vehicle
for patch testing might be inadequate, or simultaneous
Table 2. Results of patch testswith clindamycinand other allergens
Clindamycin to 10% pet.Patient
no. D2 D3/D4 Other patch tests





2 — — Thiuram mix ++
Colophonium ++
Myroxylon pereirae ++




3 — — —
4 — — —
5 — — —
6 ++ ++ —
7 — — —
8 — — —
9 — — —
10 — — —
11 — + —
12 — — Nickel ++
13 ++ ++ —
14 — — —
15 — — —
16∗ + + —
17 — — Myroxylon pereirae +
18 — — —
19 — — —
20 — — —
21 ++ ++ —
22 — — Nickel ++
Thimerosal +
23 — — Paraben mix ++
Lanolin ++
Fragrance mix II ++
Myroxylon pereirae ++
24∗ + ++ Cefoxitin ++
Fragrance mix II ++
Coumarin ++
25 ++ ++ Nickel ++
Myroxylon pereirae ++
26 + + —
27 — — Caine mix +
28 — — Colophonium ++
Lanolin ++
29 — — —
30 ++ + —
Total 9/30 (30%) 10/30 (33.3%)
∗Maculopapular exanthema upon re-exposure to clindamycin.
factors needed to trigger the reaction may not be present,
namely a concomitant drug or an acute viral infection.
There are few studies evaluating the usefulness of
patch testing with clindamycin in patients with a
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clear history of drug hypersensitivity after its systemic
administration. In this study, all patients developed mac-
ulopapular exanthema with a considerable delay after
initiation of clindamycin (mean 7.9 days) in different
infections, mostly erysipelas, but almost all patients
were using concomitant antibiotics. Positive reactions
to clindamycin, with an erythemato-papular or vesicular
pattern (+ to ++), both with pure clindamycin at 10%
pet. and with powder of the commercial capsules of clin-
damycin, also at 10% pet., with negative results in over
50 controls, show the highly specific character of this
reaction.
However, the sensitivityof theclindamycinpatch test is
rather low, as only 30%of the patch testswere positive. In
this groupof patientswhoused several concomitant drugs
for the infections, it may be possible that another drug
or the use of combined drugs or, eventually, a concomi-
tant infectious agent may have been important for the
development of the maculopapular exanthema observed
in these patients.
Nevertheless, we observed higher reactivity to clin-
damycin in the patch tests than in previously published
studies, in which the reactivity varied between 15% and
19%. Lammintausta et al. found positive patch test reac-
tions to clindamycin in 12 of the 63 patients (19%),
but the clinical charts of the tested patients were not
described in detail (1), and Seitz et al. observed positive
test reactions in 15% (5/33) of the patients (14). In this
study, at least 4 of the 28 negative results (14.3%) were
false-negative results, as oral rechallenge was positive.
Also, Notman et al., who used only prick and intrader-
mal skin tests (without assessing patch tests), obtained a
negative predictive value of just 68% (2), and suggested
that these immediate skin tests were not useful. How-
ever, in this study, both immediate and delayed adverse
drug reactions were included and, on the other hand,
delayed readings of intradermal tests were not performed
systematically, which might have changed the results.
Actually, two of these patients spontaneously reported
late reactions to intradermal testing. Althoughwe did not
perform them in this study, intradermal tests with clin-
damycin with delayed readings, performed when patch
test results are negative, might still increase the sen-
sitivity of skin testing in studying cutaneous adverse
drug reactions involving T cell-mediated hypersensitivity
reactions to clindamycin, as occurs with aminopeni-
cillins (15, 16) Despite the low reactivity (30%) in our
study, patch tests were essential to confirm the imputabil-
ity of clindamycin in these patients. As this antibiotic
was considered to seldom cause cutaneous adverse drug
reactions (2), we always suspected that the other antibi-
otic was the cause of the maculopapular exanthema,
and in two patients with recurring erysipelas, before per-
forming patch tests, we reused clindamycin associated
with another cephalosporin, and patients developed an
accelerated maculopapular exanthema.
In contrast to our experience with its systemic use, the
broad use of topical clindamycin in acne, even though at
a lower concentration (1%), and its use in vaginal cream
at 2%has only exceptionally been associatedwith allergic
contact dermatitis, with only five cases being published in
the literature (17–21).
In conclusion, before an oral challenge, the refer-
ence standard for the diagnosis these drug eruptions, we
recommend performing patch tests with clindamycin, a
non-invasive technique, as they are safer, are specifically
relevant, and can be useful for the diagnosis, even though
they may have a low negative predictive value.
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